Beth Israel Deaconess Medical Center, Inc.

Children's Medical Center Corporation

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Joseph P Nkolola

Dan H Barouch

Stephen C Harrison

Bing Chen

Michael Scott Seaman

Dan C Barouch

Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.

Biochemically stabilized HIV-1 Env trimer vaccine

The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.

Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same

Biochemically stabilized HIV-1 env trimer vaccine

The invention features isolated human immunodeficiency virus (HIV) envelope (Env) trimers, in which the amino acid sequence of the Env polypeptides is optimized to stabilize formation of the trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.

Stabilized mosaic human immunodeficiency virus type 1 (HIV-1) GP140 envelope (ENV) trimers

Biochemically stabilized HIV-1 ENV trimer vaccine

Growing community of inventors

Watertown, MA, United States of America

Joseph P Nkolola